196 related articles for article (PubMed ID: 35804964)
1. Circulating and Tumor-Infiltrating Immune Checkpoint-Expressing CD8
Alsalman A; Al-Mterin MA; Murshed K; Alloush F; Al-Shouli ST; Toor SM; Elkord E
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804964
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
Front Immunol; 2019; 10():2936. PubMed ID: 31921188
[TBL] [Abstract][Full Text] [Related]
3. Associations of different immune checkpoints-expressing CD4
Al-Mterin MA; Murshed K; Alsalman A; Abu-Dayeh A; Elkord E
BMC Cancer; 2022 Jun; 22(1):601. PubMed ID: 35655158
[TBL] [Abstract][Full Text] [Related]
4. Correlations between Circulating and Tumor-Infiltrating CD4
Al-Mterin MA; Murshed K; Elkord E
Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455287
[TBL] [Abstract][Full Text] [Related]
5. Correlations between Circulating and Tumor-Infiltrating CD4
Al-Mterin MA; Murshed K; Elkord E
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146549
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic Profiling of Tumor-Infiltrating CD4
Sasidharan Nair V; Toor SM; Taha RZ; Ahmed AA; Kurer MA; Murshed K; Soofi ME; Ouararhni K; Alajez NM; Abu Nada M; Elkord E
Vaccines (Basel); 2020 Feb; 8(1):. PubMed ID: 32041340
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma.
Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral FoxP3
Syed Khaja AS; Toor SM; El Salhat H; Ali BR; Elkord E
Front Immunol; 2017; 8():619. PubMed ID: 28603527
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
[No Abstract] [Full Text] [Related]
11. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
13. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.
Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z
Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981
[TBL] [Abstract][Full Text] [Related]
14. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
[TBL] [Abstract][Full Text] [Related]
16. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.
Gao X; Zhu Y; Li G; Huang H; Zhang G; Wang F; Sun J; Yang Q; Zhang X; Lu B
PLoS One; 2012; 7(2):e30676. PubMed ID: 22363469
[TBL] [Abstract][Full Text] [Related]
17. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
[TBL] [Abstract][Full Text] [Related]
18. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
Saleh R; Toor SM; Khalaf S; Elkord E
Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
[No Abstract] [Full Text] [Related]
19. Novel expression of Neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases.
Chaudhary B; Elkord E
Expert Opin Ther Targets; 2015 Feb; 19(2):147-61. PubMed ID: 25351619
[TBL] [Abstract][Full Text] [Related]
20. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
Aristin Revilla S; Kranenburg O; Coffer PJ
Front Immunol; 2022; 13():903564. PubMed ID: 35874729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]